Combined plasma C‐reactive protein, interleukin 6 and YKL‐40 for detection of cancer and prognosis in patients with serious nonspecific symptoms and signs of cancer
Open Access
- 28 November 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (6) , 6675-6688
Abstract
Background and methods: Inflammation is a hallmark of cancer and its progression. Plasma levels of C‐reactive protein (CRP), interleukin‐6 (IL‐6) and YKL‐40 reflect inflammation, and are elevated in patients with cancer. This study investigated whether plasma CRP, IL‐6 and YKL‐40 had diagnostic value in 753 patients referred with nonspecific signs and symptoms of cancer to a diagnostic outpatient clinic.Results: In total, 111 patients were diagnosed with cancer within 3 months and 30 after 3 months. CRP, IL‐6 and YKL‐40 were elevated in 44%, 60% and 45% of the cancer patients, and in 15%, 33% and 25% of the patients without cancer. Elevated levels of all three markers were associated with risk of cancer within 3 months: CRP (odds ratio (OR) 4.41, 95% confidence interval (CI) 2.86–6.81), IL‐6 (OR = 2.89, 1.91–4.37) and YKL‐40 (OR = 2.42, 1.59–3.66). Multivariate explorative analyses showed that increasing values were associated with the risk of getting a cancer diagnosis (continuous scale: CRP (OR = 1.28, 1.12–1.47), carcinoembryonic antigen (CEA) (OR = 1.61, 1.41–1.98), CA19‐9 (OR = 1.15, 1.03–1.29), age (OR = 1.29, 1.02–1.63); dichotomized values: CRP (OR = 2.54, 1.39–4.66), CEA (OR = 4.22, 2.13–8.34), age (OR = 1.42, 1.13–1.80)). CRP had the highest diagnostic value (area under the curve = 0.69). Combined high CRP, IL‐6 and YKL‐40 was associated with short overall survival (HR = 3.8, 95% CI 2.5–5.9, p < 0.001).Conclusion: In conclusion, plasma CRP, IL‐6 and YKL‐40 alone or combined cannot be used to identify patients with cancer, but high levels were associated with poor prognosis. CRP may be useful to indicate whether further diagnostic evaluation is needed when patients present with nonspecific signs and symptoms of cancer.Keywords
Funding Information
- Gentofte Hospital
This publication has 45 references indexed in Scilit:
- Observational and genetic plasma YKL‐40 and cancer in 96,099 individuals from the general populationInternational Journal of Cancer, 2015
- The Danish cancer pathway for patients with serious non-specific symptoms and signs of cancer–a cross-sectional study of patient characteristics and cancer probabilityBMC Cancer, 2015
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and ElaborationPLOS Medicine, 2012
- Cancer risk by combined levels of YKL-40 and C-reactive protein in the general populationBritish Journal of Cancer, 2011
- Plasma YKL-40 levels in healthy subjects from the general populationClinica Chimica Acta, 2011
- Plasma YKL-40 and Total and Disease-Specific Mortality in the General PopulationClinical Chemistry, 2010
- Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General PopulationJournal of Clinical Oncology, 2009
- Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritisBiomarkers, 2008
- ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal CancerJournal of Clinical Oncology, 2006